Jump to main content
Jump to site search

Issue 39, 2016
Previous Article Next Article

Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells

Author affiliations

Abstract

Antimicrobial Peptides (AMPs) have unique anticancer properties, but their clinical application is currently limited by an inadequate margin of safety. A prodrug strategy associated with a combination therapy approach could address this limitation by increasing their therapeutic index and their efficacy. Accordingly, the first targeted anticancer polymeric prodrug candidates of AMPs, intended for combination therapy with another polymeric prodrug of an approved antineoplastic agent (doxorubicin), were synthesized as either a PEG-based dual-release prodrug or two individual pegylated prodrugs. The latter are based on a cathepsin B-labile peptide linker and an acid-sensitive acyl hydrazone bond for the AMP and doxorubicin prodrugs, respectively. Anticancer activities and toxicity differentials achieved with the free peptide and its polymer conjugates against ovarian, cancer and non-malignant, cells, indicate that protease-dependent reversible pegylation could be implemented to increase the therapeutic indices of AMPs in cancer therapy. The results obtained also show that this approach can be developed if the releasable PEG linker can be optimised to conciliate the attributes and restrictions of pegylation against proteases. In addition, combination of the polymeric prodrugs of the AMP and of doxorubicin provides additive antitumor effects which could be exploited to enhance the efficacy of the AMP candidate.

Graphical abstract: Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 19 Aug 2016, accepted on 06 Sep 2016 and first published on 06 Sep 2016


Article type: Paper
DOI: 10.1039/C6OB01815G
Org. Biomol. Chem., 2016,14, 9278-9286

  •   Request permissions

    Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells

    G. J. Kelly, A. F. Kia, F. Hassan, S. O'Grady, M. P. Morgan, B. S. Creaven, S. McClean, J. H. Harmey and M. Devocelle, Org. Biomol. Chem., 2016, 14, 9278
    DOI: 10.1039/C6OB01815G

Search articles by author

Spotlight

Advertisements